FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897119980> ?p ?o ?g. }

• W2897119980 endingPage "434" @default.
• W2897119980 startingPage "425" @default.
• W2897119980 abstract "The combination of kappa-carrageenan (κ-CG) and hydroxyapatite (HA) to generate a bone substitute material has been underexplored to date. Carrageenans (CGs) have remarkable characteristics such as biocompatibility, hydrophilicity, and structural similarities with natural glycosaminoglycans (GAGs), and they have demonstrated the ability to stimulate cellular adhesion and proliferation. Hydroxyapatite nanoparticles have been one of the most investigated materials for bone regeneration due to their excellent biocompatibility, bioactivity and osteoconductivity. In particular, this study presents an approach for the preparation of new bioactive composites of κ-CG/nHA for numerous bone regeneration applications. We performed a set of in vitro experiments to evaluate the influence of the bone substitutes on human osteoblasts. Cell culture studies indicated that all samples tested were cytocompatible. Relative to control substrates, cellular attachment and proliferation were better on all the scaffold surfaces that were tested. The S2 and S3 samples, those permeated by 1.5 and 2.5 wt% of CG, respectively, exhibited an enhancement in cell spreading capacity compared to the S1 test materials which were comprised of 1 wt% of CG. Excellent osteoblast viability and adhesion were observed for each of the tested materials. Additionally, the bone substitutes developed for this study presented a distinct osteoconductive environment. Data supporting this claim were derived from alkaline phosphatase (ALP) and calcium deposition analyses, which indicated that, compared to the control species, ALP expression and calcium deposition were both improved on test κ-CG/nHA surfaces. In summary, the injectable bone substitute developed here demonstrated great potential for numerous bone regeneration applications, and thus, should be studied further. The novelty of this work lies in the determination of the in vitro cytocompatibility behavior of carrageenan and hydroxyapatite composite materials used as injectable bone substitutes. This injectable biomaterial can fill in geometric complex defects, and it displays bioactivity as well as high bone regeneration capacity. In this study, we evaluated the behaviors of osteoblast cells in contact with the scaffolds, including cellular adhesion and proliferation, cellular metabolism, and mineralization on the fabricated injectable bone substitutes. The results show than the carrageenan and hydroxyapatite substitutes provided a biomaterial with a great capacity for promoting cellular growth, adhesion, and proliferation, as well as contributing an osteoinductive environment for osteoblast differentiation and osteogenesis." @default.
• W2897119980 created "2018-10-26" @default.
• W2897119980 creator A5005977451 @default.
• W2897119980 creator A5008365184 @default.
• W2897119980 creator A5022948065 @default.
• W2897119980 creator A5025353360 @default.
• W2897119980 creator A5072008894 @default.
• W2897119980 creator A5082598670 @default.
• W2897119980 date "2019-01-01" @default.
• W2897119980 modified "2023-10-17" @default.
• W2897119980 title "Osteoblast responses to injectable bone substitutes of kappa-carrageenan and nano hydroxyapatite" @default.
• W2897119980 cites W1535135748 @default.
• W2897119980 cites W1885730468 @default.
• W2897119980 cites W1904701236 @default.
• W2897119980 cites W1980326094 @default.
• W2897119980 cites W1981758340 @default.
• W2897119980 cites W1993882629 @default.
• W2897119980 cites W2003584427 @default.
• W2897119980 cites W2011557430 @default.
• W2897119980 cites W2014504563 @default.
• W2897119980 cites W2023764021 @default.
• W2897119980 cites W2031395064 @default.
• W2897119980 cites W2032469985 @default.
• W2897119980 cites W2034028595 @default.
• W2897119980 cites W2036894851 @default.
• W2897119980 cites W2042931947 @default.
• W2897119980 cites W2043525625 @default.
• W2897119980 cites W2053030583 @default.
• W2897119980 cites W2055308232 @default.
• W2897119980 cites W2056394734 @default.
• W2897119980 cites W2064600837 @default.
• W2897119980 cites W2065926330 @default.
• W2897119980 cites W2066765932 @default.
• W2897119980 cites W2073073851 @default.
• W2897119980 cites W2076740646 @default.
• W2897119980 cites W2078713276 @default.
• W2897119980 cites W2081459547 @default.
• W2897119980 cites W2081564713 @default.
• W2897119980 cites W2087465408 @default.
• W2897119980 cites W2089162996 @default.
• W2897119980 cites W2089264492 @default.
• W2897119980 cites W2099387542 @default.
• W2897119980 cites W2148820762 @default.
• W2897119980 cites W2156040657 @default.
• W2897119980 cites W2178706952 @default.
• W2897119980 cites W2192021939 @default.
• W2897119980 cites W2313531836 @default.
• W2897119980 cites W2320658503 @default.
• W2897119980 cites W2409906727 @default.
• W2897119980 cites W2471112897 @default.
• W2897119980 cites W2523539001 @default.
• W2897119980 cites W2557638772 @default.
• W2897119980 cites W2580683704 @default.
• W2897119980 cites W2582794564 @default.
• W2897119980 cites W2761370985 @default.
• W2897119980 cites W3146755591 @default.
• W2897119980 doi "https://doi.org/10.1016/j.actbio.2018.10.023" @default.
• W2897119980 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30342285" @default.
• W2897119980 hasPublicationYear "2019" @default.
• W2897119980 type Work @default.
• W2897119980 sameAs 2897119980 @default.
• W2897119980 citedByCount "50" @default.
• W2897119980 countsByYear W28971199802019 @default.
• W2897119980 countsByYear W28971199802020 @default.
• W2897119980 countsByYear W28971199802021 @default.
• W2897119980 countsByYear W28971199802022 @default.
• W2897119980 countsByYear W28971199802023 @default.
• W2897119980 crossrefType "journal-article" @default.
• W2897119980 hasAuthorship W2897119980A5005977451 @default.
• W2897119980 hasAuthorship W2897119980A5008365184 @default.
• W2897119980 hasAuthorship W2897119980A5022948065 @default.
• W2897119980 hasAuthorship W2897119980A5025353360 @default.
• W2897119980 hasAuthorship W2897119980A5072008894 @default.
• W2897119980 hasAuthorship W2897119980A5082598670 @default.
• W2897119980 hasConcept C105702510 @default.
• W2897119980 hasConcept C136229726 @default.
• W2897119980 hasConcept C159985019 @default.
• W2897119980 hasConcept C160160445 @default.
• W2897119980 hasConcept C171056886 @default.
• W2897119980 hasConcept C181199279 @default.
• W2897119980 hasConcept C185592680 @default.
• W2897119980 hasConcept C191897082 @default.
• W2897119980 hasConcept C192562407 @default.
• W2897119980 hasConcept C202751555 @default.
• W2897119980 hasConcept C2777230088 @default.
• W2897119980 hasConcept C2778260815 @default.
• W2897119980 hasConcept C55493867 @default.
• W2897119980 hasConcept C71924100 @default.
• W2897119980 hasConcept C8337478 @default.
• W2897119980 hasConcept C84416704 @default.
• W2897119980 hasConcept C85789140 @default.
• W2897119980 hasConcept C86803240 @default.
• W2897119980 hasConcept C89429830 @default.
• W2897119980 hasConcept C95444343 @default.
• W2897119980 hasConceptScore W2897119980C105702510 @default.
• W2897119980 hasConceptScore W2897119980C136229726 @default.
• W2897119980 hasConceptScore W2897119980C159985019 @default.
• W2897119980 hasConceptScore W2897119980C160160445 @default.

• next